Equities

KPC Pharmaceuticals Inc

600422:SHH

KPC Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)12.06
  • Today's Change-0.24 / -1.95%
  • Shares traded11.12m
  • 1 Year change-28.85%
  • Beta0.9566
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,9701,8661,620
Total Receivables, Net3,1112,8182,180
Total Inventory1,6881,6811,884
Prepaid expenses136244382
Other current assets, total127158115
Total current assets7,0316,7666,180
Property, plant & equipment, net1,2501,2911,361
Goodwill, net929292
Intangibles, net525530609
Long term investments342346280
Note receivable - long term------
Other long term assets1945--
Total assets9,5659,4328,893
LIABILITIES
Accounts payable665693628
Accrued expenses1,4381,2621,109
Notes payable/short-term debt1,0511,2531,339
Current portion long-term debt/capital leases2312236
Other current liabilities, total467559372
Total current liabilities3,6443,8893,485
Total long term debt152105150
Total debt1,2261,4801,526
Deferred income tax8.301115
Minority interest179159157
Other liabilities, total284285302
Total liabilities4,2684,4494,110
SHAREHOLDERS EQUITY
Common stock758758758
Additional paid-in capital1,1581,1611,169
Retained earnings (accumulated deficit)3,3963,0732,897
Treasury stock - common(10)(13)(26)
Unrealized gain (loss)------
Other equity, total(4.09)3.81(14)
Total equity5,2974,9834,783
Total liabilities & shareholders' equity9,5659,4328,893
Total common shares outstanding757757758
Treasury shares - common primary issue1.011.280
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.